Anaptis Bio, now a virtual royalty company after its April 20th separation, expects Jemperly royalties to grow with the rectal cancer approval. The CEO's best guess for a Delaware court decision in its GSK litigation is December or January.
ANAB · Anaptysbio, Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 54%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Jan 2020 to Nov 2026
The closing range begins at the captured split on Apr 20, 2026.
Up next
Latest documents
AnaptysBio reported $30.3 million in collaboration revenue for the three months ended September 30, 2026, down from $76.3 million, while Jemperli received accelerated FDA approval for previously untreated stage II and III dMMR/MSI-H locally advanced rectal cancer.
AnaptysBio reported Jemperli global net sales of $1.0 billion (£753 million) through September 30, 2026, up 29% year-over-year, and U.S. approval in stage II and III MSI-H/dMMR locally advanced rectal cancer. A GSK and Tesaro judgment is anticipated in calendar Q4 2026 or Q1 2027.
AnaptysBio, Inc. reported Jemperli sales of $644 million (£480 million) for the six months ended June 30, 2026, up 34% year-over-year; collaboration revenue was $53.0 million and net income from continuing operations was $176.4 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Jemperli non-cash royalty revenue | $29.6M | the three months ended September 30, 2026 filing | — |
|
|
|||
| Non-cash interest expense | $19M | the three months ended September 30, 2026 filing | — |
| Royalties and sales milestones accrued | $330M | through September 30, 2026 | — |
| Zejula non-cash revenue | $0.7M | the three months ended September 30, 2026 filing | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANAB
this stock
Anaptysbio, Inc
|
$1.39B | — | +157.0% | — | 16.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 23
Anaptis Bio, now a virtual royalty company after its April 20th separation, expects Jemperly royalties to grow with the rectal cancer approval. The CEO's best guess for a Delaware court decision in its GSK litigation is December or January.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANAB | +0.8% | -4.3% | -9.0% | -3.4% | +44.3% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +9.4% | +4.9% | +0.2% | +5.3% | +43.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.